Phosphodiesterase 4 Inhibitors

08/01/2005 - "Together with their potent anti-inflammatory properties, the potentially enhanced airway mucociliary clearance from CFTR activation may have contributed to the efficacy of PDE4 inhibitors in COPD and asthmatic patients. "
08/01/2011 - "[Are phosphodiesterase 4 inhibitors really helpful in COPD?]."
01/01/2013 - "Longer-term trials are needed to determine whether or not PDE4 inhibitors modify FEV1 decline, hospitalisation or mortality in COPD."
01/01/2011 - "Longer-term trials are needed to determine whether or not PDE(4) inhibitors modify FEV(1) decline, healthcare utilisation or mortality in COPD."
12/01/2015 - "Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs."

12/01/1997 - "Over the last few years, evidence has accumulated that cyclic nucleotide phosphodiesterase (PDE) 3 and/or PDE4 inhibitors may be useful for the treatment of asthma. "
01/01/2003 - "The development of phosphodiesterase (PDE)4 inhibitors is one such approach, and recent studies have demonstrated the potential utility of this new drug class for the treatment of patients with asthma.(2)"
12/01/2010 - "These findings provide proof of concept that PDE4 inhibitors with PDE4B selectivity may have efficacy in asthma treatment."
06/17/2002 - "8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma."
09/18/2000 - "7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma."

01/01/2001 - "These studies suggest that the ferret is an appropriate model to study emesis induced by PDE4 inhibitors and that these compounds trigger the emetic reflex via a noradrenergic pathway, mimicking the pharmacological actions of a pre-synaptic alpha(2)-adrenoceptor inhibition."
01/01/2012 - "Although PDE4 inhibitors induce emesis by mimicking the pharmacological action of an α(2)-adrenoceptor antagonist, repeated administration of ASP3258 (3 mg/kg) had no such inhibitory effect on rats anesthetized with α(2) - adrenoceptor agonist. "
06/01/2011 - "PDE4 inhibitors induce emesis by mimicking the pharmacological action of α(2)-adrenoceptor antagonist. "
01/05/2011 - "However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis. "
09/01/2010 - "Emesis is one of the most common side effects of PDE4 inhibitors. "

03/01/2007 - "Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis."
01/01/2011 - "Consequently, there is intense interest in the development of selective PDE4 inhibitors for the treatment of a range of inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and psoriasis. "
09/01/2010 - "PDE4 inhibitors are currently under development for the treatment of inflammatory diseases, such as asthma, chronic pulmonary diseases, and psoriasis, and for treating depression and serving as cognitive enhancers. "
05/01/2007 - "In principle, therapeutic intervention of an inflammatory response by PDE4 inhibitors may be extended to other chronic inflammatory disease states such as psoriasis, rheumatoid arthritis and inflammatory bowel diseases (e.g., Crohns disease and ulcerative colitis). "
05/01/2014 - "To describe important aspects of phosphodiesterase inhibition and the safety and efficacy of 2 phosphodiesterase- 4 inhibitors being studied for the treatment of dermatologic diseases We did a non-systematic analysis of literature on phosphodiesterase inhibition followed by a review of published information on apremilast and topical AN2728 and their use for psoriasis and atopic dermatitis. "

06/15/2005 - "Cyclic nucleotide PDE4 (phosphodiesterase 4) inhibitors are being developed as potent anti-inflammatory drugs for use in chronic lung diseases, but the complexity of the PDE4 family has hampered this process. "
03/01/2005 - "Since inflammatory diseases of the bronchial airways are associated with destruction of normal tissue structure, our data suggest a therapeutic benefit for PDE4 inhibitors in tissue remodelling associated with chronic lung diseases."
01/01/2015 - "Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases."
01/01/2011 - "Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies."
08/01/2002 - "These rolipram-sensitive features suggest the potential of PDE4 inhibitors in chronic inflammatory lung diseases."